A team of cardiologists is designing a randomized, double-blind, placebo-controlled trial to evaluate the efficacy of a novel sodium-glucose cotransporter-2 (SGLT2) inhibitor in reducing heart failure exacerbations among patients with preserved ejection fraction. The primary endpoint is the number of hospital admissions for heart failure over a 12-month period. Preliminary sample size calculations using a predetermined significance level () of 0.05 yield a statistical power of 65%. The investigators wish to modify the trial design to achieve a minimum power of 80% to ensure they do not miss a clinically significant benefit.
Which of the following adjustments to the study design would independently increase the statistical power of this trial? (Select all that apply)
- Expanding the recruitment target to enroll a larger number of total participantsCevap
- BBroadening the inclusion criteria to create a clinically more heterogeneous study population
- CDecreasing the predetermined significance level () for the primary analysis from 0.05 to 0.01
- Employing a rigorous, centralized adjudication process for the primary endpoint to decrease outcome variabilityCevap
- EAltering the randomization allocation ratio between the treatment and placebo groups from 1:1 to 2:1 while maintaining the same total sample size